magnifying glass
logo for Caraway Therapeutics

Caraway Therapeutics

Get Full Access

Who is Caraway Therapeutics

Caraway Therapeutics is a biopharmaceutical company pursuing novel approaches for the treatment of genetically defined neurodegenerative and rare diseases. Thecompany is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function. Caraway is utilizing its unique product engine to develop proprietary insights into lysosomal function and small molecule ion channel modulation and advance a robust pipeline of precision therapeutic candidates with disease-modifying potential for patients. The company is backed by top-tier investors, including SV Health Investors, AbbVie Ventures, MRLV Fund, Amgen Ventures, Dementia Discovery Fund, Alexandria Venture Investments and Eisai Innovation.Read More



300 Technology Sq, Fl 2, Cambridge, Massachusetts, 02139, United States
Phone Number

Phone Number:

(617) 245-8188




<$5 Million
Caraway Therapeutics's Social Media
SIC Code 87,873
NAICS Code 541,541714
Popular Searches:

Caraway Therapeutics Inc

Caraway Therapeutics

Rheostat Therapeutics

Rheostat Therapeutics Inc


Caraway Therapeutics's Org Chart

Martin Williams
Martin Williams

Chief Executive Officer

Rhonda Chicko
Rhonda Chicko

Chief Financial Officer

Magdalene Moran
Magdalene Moran

President & Chief Scientific Office...


Illustration of an envelope

Caraway Therapeutics's Tech Stack




Business Wire


Business Wire




Microsoft Word


See more technologies

Caraway Therapeutics News & Media

Caraway Therapeutics to Participate at Two Upcoming Investor Events

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics announces a presentation at the Stifel CNS Days and participation in the 21st Annual Needham Virtual Healthcare Conference

Caraway Therapeutics to Present at Oppenheimer 32nd Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics announces that CEO Martin D. Williams will be presenting at the Oppenheimer 32nd Annual Healthcare Conference

Caraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced the appointment of David Clapham, MD, PhD, to the company’s Scientific Advisory Board (SAB)
Subscribe to "Caraway Therapeutics" News

Frequently Asked Questions regarding Caraway Therapeutics

Where are Caraway Therapeutics’s headquarters?

Caraway Therapeutics’s headquarters are in 300 Technology Sq, Fl 2, Cambridge, Massachusetts, 02139, United States

What is Caraway Therapeutics’s phone number?

Caraway Therapeutics’s phone number is (617) 245-8188

What is Caraway Therapeutics’s official website?

Caraway Therapeutics’s official website is

What is Caraway Therapeutics’s Revenue?

Caraway Therapeutics’s revenue is <$5 Million

What is Caraway Therapeutics’s SIC code?

Caraway Therapeutics’s SIC: 87,873

What is Caraway Therapeutics’s NAICS code?

Caraway Therapeutics’s NAICS: 541,541714

How many employees are working in Caraway Therapeutics?

Caraway Therapeutics has <25 employees

What is Caraway Therapeutics’s industry?

Caraway Therapeutics is in the industry of: Biotechnology, Pharmaceuticals, Healthcare

What is Caraway Therapeutics's tech stack?

The technologies that are used by Caraway Therapeutics are: ASP.NET, Business Wire, PHP, Microsoft Word

Who is Caraway Therapeutics's CEO?

Caraway Therapeutics's CEO is Martin Williams

Who is Caraway Therapeutics's CFO?

Caraway Therapeutics's CFO is Rhonda Chicko

See more information about Caraway Therapeutics
4.4/5 on G2 Crowd